



Paxil® (paroxetine hydrochloride) – First-time generic

- On September 10, 2021, Novitium launched an [AB-rated](#) generic version of Apotex's [Paxil \(paroxetine hydrochloride\)](#) oral suspension.
- Paxil is approved in adults for the treatment of major depressive disorder (MDD), obsessive compulsive disorder (OCD), panic disorder (PD), social anxiety disorder (SAD), generalized anxiety disorder (GAD), and posttraumatic stress disorder.
- Paroxetine hydrochloride is also available generically as [tablets](#) and [extended-release tablets](#) and generically as paroxetine [capsules](#), and brand paroxetine mesylate tablets ([Pexeva](#)®).
 - The tablets carry the same indication as Paxil suspension.
 - The extended-release tablets are approved for adults for the treatment of MDD, PD, SAD and premenstrual dysphoric disorder.
 - The capsules are approved for the treatment of moderate to severe vasomotor symptoms associated with menopause.
 - Pexeva is approved for adults for the treatment of MDD, OCD, PD, and GAD.
- Paxil carries a boxed warning for suicidal thoughts and behaviors.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.